News & Updates

Show Multimedia Only

C-index predicts adverse outcomes, death in anticoagulated patients with AF

08 Apr 2026

The conicity index (C-index) appears to be the most robust and most consistent prognostic value among adiposity indices in anticoagulated patients with atrial fibrillation (AF), suggests a study.

C-index predicts adverse outcomes, death in anticoagulated patients with AF

08 Apr 2026

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

08 Apr 2026

Initiation of an SGLT2 inhibitor, relative to a GLP-1 receptor agonist (RA), results in a lower risk of adverse kidney events among patients with stage 2 diabetes and stage 4‒5 chronic kidney disease (CKD), with similar cardiovascular and mortality risks, a study has shown.

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

08 Apr 2026

$Weight maintenance after smoking cessation lowers fracture risk in men with T2DM$

Weight maintenance after smoking cessation lowers fracture risk in men with T2DM

07 Apr 2026

Quitting smoking does not appear to contribute to a decrease in fracture risk in male patients newly diagnosed with type 2 diabetes mellitus (T2DM), but maintaining weight following cessation may help, reveals a study. Moreover, weight loss after quitting tends to increase such risk.

Weight maintenance after smoking cessation lowers fracture risk in men with T2DM

07 Apr 2026

High intakes of dietary calcium, dairy products may protect against MetS

06 Apr 2026

Adults who have high dietary calcium and dairy product intakes are less likely to develop metabolic syndrome (MetS), suggests a meta-analysis.

High intakes of dietary calcium, dairy products may protect against MetS

06 Apr 2026

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

06 Apr 2026

In adult patients with diabetes and epilepsy, treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with lower risks of seizure recurrence, hospitalization, and mortality compared with other glucose-lowering therapies, according to a retrospective study.

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

06 Apr 2026

More evidence supports healthy lifestyle adoption for hypertension management

05 Apr 2026

For adults with hypertension, maintaining a healthy lifestyle may help prevent the development of major cardiometabolic disease regardless of antihypertensive medication use, as shown in a study.

More evidence supports healthy lifestyle adoption for hypertension management

05 Apr 2026

Hormone therapy augments weight-loss response with tirzepatide in postmenopausal women

03 Apr 2026 by

In postmenopausal women receiving treatment with tirzepatide for overweight or obesity, concurrent use of hormone therapy confers greater reduction in weight as well as improvement in cardiometabolic outcomes, according to a retrospective cohort study.

Hormone therapy augments weight-loss response with tirzepatide in postmenopausal women

03 Apr 2026

Glucose level affects immunotherapy efficacy in NSCLC

02 Apr 2026 by

A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).

Glucose level affects immunotherapy efficacy in NSCLC

02 Apr 2026

Orforglipron: The new kid on the weight loss runway?

31 Mar 2026 by

The novel oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) orforglipron gains the upper hand over the current leading oral GLP-1 RA, semaglutide, in individuals with type 2 diabetes (T2D) inadequately controlled on metformin in the phase III ACHIEVE-3 study.

Orforglipron: The new kid on the weight loss runway?

31 Mar 2026

Denosumab after a decade of Tx: Subsequent strategies and BMD trajectories

30 Mar 2026 by

Continuing denosumab beyond 10 years results in further increases in lumbar spine bone mineral density (BMD) and preserves femoral neck BMD, while switching to zoledronic acid leads to partial loss of previous gains and switching to romosozumab produces additional BMD gain at the lumbar spine, a cohort study in Hong Kong has shown.

Denosumab after a decade of Tx: Subsequent strategies and BMD trajectories

30 Mar 2026

News & Updates

Showing Endocrinology articles

Showing

Specialty:

C-index predicts adverse outcomes, death in anticoagulated patients with AF

C-index predicts adverse outcomes, death in anticoagulated patients with AF

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

SGLT2 inhibitor vs GLP-1 RA: Which is better for CKD patients with diabetes?

Weight maintenance after smoking cessation lowers fracture risk in men with T2DM

Weight maintenance after smoking cessation lowers fracture risk in men with T2DM

High intakes of dietary calcium, dairy products may protect against MetS

High intakes of dietary calcium, dairy products may protect against MetS

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

More evidence supports healthy lifestyle adoption for hypertension management

More evidence supports healthy lifestyle adoption for hypertension management

Hormone therapy augments weight-loss response with tirzepatide in postmenopausal women

Hormone therapy augments weight-loss response with tirzepatide in postmenopausal women

Glucose level affects immunotherapy efficacy in NSCLC

Glucose level affects immunotherapy efficacy in NSCLC

Orforglipron: The new kid on the weight loss runway?

Orforglipron: The new kid on the weight loss runway?

Denosumab after a decade of Tx: Subsequent strategies and BMD trajectories

Denosumab after a decade of Tx: Subsequent strategies and BMD trajectories